文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-DOTA-JR11在转移性神经内分泌肿瘤患者中的生物分布与辐射剂量估计

Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-10-29

前瞻性研究纳入20例晚期NET患者,注射169 MBq(中位数)68Ga-DOTA-JR11后60分钟行全身PET/CT,分析42个病灶。结果显示肿瘤摄取快速、肿瘤/本底比值高、血清除快,肝本底低;膀胱壁和肾脏吸收剂量最高,有效剂量为0.022 mSv/MBq。

要点

  • 68Ga-DOTA-JR11在NET中肿瘤摄取快速,注射后20-30分钟达平台,肿瘤SUVmax中位数13.0。
  • 肝本底低(SUVmean中位数1.1),可能有利于肝转移灶检测。
  • 膀胱壁吸收剂量最高(0.30 mGy/MBq),有效剂量为0.022 mSv/MBq。

核心结论

  • 68Ga-DOTA-JR11在NET患者中显示快速肿瘤摄取、高肿瘤/本底比值和快速血清除,低肝本底可能有利于肝转移检测。
  • 剂量学数据与已发表的68Ga-DOTATATE和68Ga-DOTATOC数据相比具有优势。

研究设计与样本

  • 前瞻性研究,20例晚期NET患者接受全身PET/CT成像(注射68Ga-DOTA-JR11后60分钟,中位剂量169 MBq)。
  • 分析每例患者最多4个摄取高于肝脏的68Ga-DOTA-JR11 avid病灶,计算SUV和靶/非靶比值。
  • 6例患者亚组接受额外动态扫描(上腹部25分钟,部分包含左心室、肝、脾、肾)和注射后30分钟全身PET/CT,用于确定示踪剂分布时程和辐射剂量估计。
  • 吸收剂量使用OLINDA/EXM 1.0计算。

主要发现

  • 与已知的生长抑素受体激动剂生物分布不同,垂体、脾、肾上腺和无受累肝脏中几乎或没有高于本底的摄取;脾SUVmean中位数1.4(范围0.7-1.8),肝SUVmean 1.1(0.7-1.9)。
  • 共分析42个肿瘤病灶,SUVmax中位数13.0(范围2.9-94),TNR血液9.3(1.8-87),TNR脾4.9(1.9-48),TNR肾2.2(0.52-28),TNR肝10.5(2.3-107)。
  • 肿瘤摄取在注射后20-30分钟达到平台水平。
  • 正常组织最高吸收剂量估计(mGy/MBq):膀胱壁0.30(SD 0.06),肾脏0.050(SD 0.013)。
  • 有效剂量(ICRP 103)为0.022(SD 0.003)mSv/MBq。

临床怎么用

  • 68Ga-DOTA-JR11 PET/CT可用于NET成像,注射后60分钟成像显示快速肿瘤摄取和高肿瘤/本底比值。
  • 低肝本底可能有利于肝转移灶的检测。
  • 剂量学数据可与68Ga-DOTATATE和68Ga-DOTATOC比较,但需进一步临床验证。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Somatostatin receptor antagonists have shown promise for imaging neuroendocrine tumors (NETs) in preclinical studies, but clinical data is still very limited. In this study, we assess the feasibility of using the novel somatostatin antagonist 68Ga-DOTA-JR11 for PET imaging of NETs. METHODS: Twenty patients with advanced NETs underwent whole-body PET/CT imaging 60 min after injection of 169 MBq (median) 68Ga-DOTA-JR11 as part of a prospective study. Volumes of interest were drawn around up to four 68Ga-DOTA-JR11-avid lesions per patient (with uptake greater than liver) and standardized uptake values were estimated. Additionally, target-to-normal tissue ratios were calculated. A subset of six patients had additional imaging (25-min dynamic scan of the upper abdomen including, at least partly, cardiac left ventricle, liver, spleen, and kidney, and a whole-body PET/CT scan at 30 min post-injection) to determine the time course of tracer distribution and facilitate radiation dose estimates. Absorbed doses were calculated using OLINDA/EXM 1.0. RESULTS: In contrast to the known biodistribution of somatostatin receptor agonists, little or no uptake above background was seen in the pituitary gland, spleen, adrenals, and uninvolved liver; e.g., median spleen SUVmean 1.4 (range: 0.7-1.8), liver SUVmean 1.1 (0.7-1.9). A total of 42 tumor lesions were analyzed with median SUVmax 13.0 (range: 2.9-94), TNR blood 9.3 (1.8-87), TNR spleen 4.9 (1.9-48), TNR kidney 2.2 (0.52-28), and TNR liver 10.5 (2.3-107). Tumor uptake reached plateau levels by 20-30 min post-injection. The highest absorbed dose estimates (mGy/MBq) to normal tissues were: urinary bladder wall (0.30; SD 0.06) and kidneys (0.050; SD 0.013). The effective dose (ICRP 103) was 0.022 (SD 0.003) mSv/MBq. CONCLUSIONS: 68Ga-DOTA-JR11 demonstrated rapid tumor uptake, high tumor/background ratios, and rapid clearance from blood. The low liver background is advantageous and may facilitate detection of liver metastases. Dosimetric data compare favorably with published data for 68Ga-DOTATATE and 68Ga-DOTATOC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Krebs S, Pandit-Taskar N, Reidy D, et al. Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2018. PMID: 30374529. doi:10.1007/s00259-018-4193-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。